Publicaciones en las que colabora con Álvaro Pascual (74)

2024

  1. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

    Infection

2023

  1. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

  2. Diagnostic tool for surveillance, detection and monitoring of the high-risk clone K. pneumoniae ST15

    Journal of Hospital Infection, Vol. 142, pp. 18-25

  3. Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae

    Microbiology Spectrum, Vol. 11, Núm. 2

2022

  1. Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PaβN): co-resistance to antimicrobials

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1272-1281

  2. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

  3. Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

  4. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

  5. Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software

    Frontiers in Microbiology, Vol. 12

  6. Phenotypic and genomic comparison of klebsiella pneumoniae lytic phages: Vb_kpnm-vac66 and vb_kpnm-vac13

    Viruses, Vol. 14, Núm. 1

  7. The role of PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains in lytic phage infection

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnMVAC13 against clinical isolates of klebsiella pneumoniae

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 9

2020

  1. First identification of blaNDM-1 carbapenemase in blaOXA-94-producing Acinetobacter baumannii ST85 in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 11-15

  2. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

    Microbial Genomics, Vol. 6, Núm. 5, pp. 1-18

  3. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

    Scientific Reports, Vol. 10, Núm. 1

  4. Mechanisms of tolerance and resistance to chlorhexidine in clinical strains of Klebsiella pneumoniae producers of carbapenemase: Role of new type II toxin-antitoxin system, PemIK

    Toxins, Vol. 12, Núm. 9

  5. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  6. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Combined use of the Ab105-2ϕ∆CI lytic mutant phage and different antibiotics in clinical isolates of multi-resistant Acinetobacter baumannii

    Microorganisms, Vol. 7, Núm. 11

  2. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1244-1252